Plymouth-based Celsee Diagnostics firm is currently building out its team and growing revenue streams that support its cancer-detection technology.
The life sciences startup formerly known as DeNovo Sciences employs 11 full-time employees and 10 part-time employees after hiring two more over the last year. Those new hires include a new chief science officer and vice president of commercial operations.
"We're building out a leadership team to get our commercialization up and moving quickly," says Kalyan Handique, CEO of Celsee Diagnostics
Celsee Diagnostics is developing a platform for early detection of cancer from blood samples. Its fully automated system can detect cancer, primarily breast and colon cancers. The idea is to create a less-invasive method than the traditionally painful route of biopsies. Celsee is in the midst of starting clinical trials on this platform. The trials for European approval are expected to be done within six months. U.S. trials are expected to run into next year.
Celsee Diagnostics also raised a small amount of money from investors last year, but it is focusing on generating more revenues to cover its expenses, selling its platform to researchers in the U.S. and overseas.
"We expect to cross $1 million this year," Handique says. "It will make investing in our product easier."
Celsee Diagnostics is also selling its platform in Israel and some developing countries, including Brazil and China.
"We're starting to get more traction in those countries," Handique says.
Source: Kalyan Handique, CEO of Celsee Diagnostics
Writer: Jon Zemke